Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-09-04

Shanxi Multiple Myeloma Active Trials & Centers

As of 2026-09-04, there are 20 active clinical trials for multiple myeloma hosted across 8 tertiary medical centers in Shanxi (including Shanxi Cancer Hospital, Yuncheng Central Hospital, Shanxi Province, Heping Hospital Affiliated to Changzhi Medical College, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (8)

Shanxi Cancer HospitalYuncheng Central Hospital, Shanxi ProvinceHeping Hospital Affiliated to Changzhi Medical College山西医科大学第一医院山西白求恩医院Second Hospital of Shanxi Medical UniversityShanxi Provincial People's HospitalDatong Third People's Hospital

Active Studies in Shanxi (20)

Population synthesized by CMDN

Showing 0 published English records of 20 registry trials.

All 20 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub